enGene Therapeutics is developing Detalimogene, a non‑viral gene‑therapy platform for intravesical treatment of non‑muscle invasive bladder cancer (NMIBC). The synthetic delivery system enables localized gene transfer to bladder tumor cells, avoiding viral immunogenicity and simplifying manufacturing while aiming for durable anti‑tumor activity with minimal systemic exposure.
Funding
$43.2M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Non‑muscle invasive bladder cancer (NMIBC) often requires repeated intravesical therapies, yet current treatments can have limited efficacy, safety concerns, and logistical challenges associated with viral gene‑delivery platforms.
Solution
enGene Therapeutics is developing Detalimogene, a non‑viral gene‑therapy platform designed for intravesical administration in NMIBC patients. By using a synthetic, non‑viral delivery system, the therapy aims to introduce therapeutic genes directly into bladder tumor cells without the immunogenicity and manufacturing complexities of viral vectors. The approach seeks to achieve durable anti‑tumor activity while minimizing systemic exposure and adverse events. enGene’s platform leverages proprietary formulation technology to enhance cellular uptake and gene expression within the bladder epithelium, offering a potentially more convenient and repeatable treatment option for clinicians.
Target Audience
Primary customers are urologists and oncologists treating NMIBC, as well as pharmaceutical partners seeking to develop localized gene‑therapy solutions for bladder cancer.
Features
- Non‑viral vector formulation that avoids viral immunogenicity and simplifies manufacturing
- Intravesical delivery optimized for localized gene transfer to bladder urothelium
- Proprietary carrier system designed to improve cellular uptake and sustained gene expression
- Scalable platform compatible with multiple therapeutic gene candidates for bladder cancer
- Preclinical data indicating targeted activity with reduced systemic toxicity